Oxford BioMedica (OTCMKTS:OXBDF) Downgraded to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Oxford BioMedica (OTCMKTS:OXBDF) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Separately, HC Wainwright restated a buy rating and issued a $14.50 price objective on shares of Oxford BioMedica in a research note on Wednesday, September 4th.

Shares of Oxford BioMedica stock traded up $0.16 during midday trading on Wednesday, hitting $7.21. The company had a trading volume of 1,235 shares, compared to its average volume of 472. The business’s 50 day simple moving average is $6.89 and its two-hundred day simple moving average is $8.14. The stock has a market cap of $473.19 million, a PE ratio of 48.03 and a beta of 0.77. Oxford BioMedica has a 1-year low of $6.20 and a 1-year high of $10.02.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Further Reading: What is a Candlestick Chart?

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect United Continental Holdings Inc  to Post $2.63 Earnings Per Share
Zacks: Analysts Expect United Continental Holdings Inc to Post $2.63 Earnings Per Share
Brokerages Anticipate Tripadvisor Inc  Will Announce Quarterly Sales of $334.77 Million
Brokerages Anticipate Tripadvisor Inc Will Announce Quarterly Sales of $334.77 Million
Waltonchain Price Down 6.8% This Week
Waltonchain Price Down 6.8% This Week
QuickX Protocol 24 Hour Trading Volume Hits $312,537.00
QuickX Protocol 24 Hour Trading Volume Hits $312,537.00
SophiaTX Market Capitalization Achieves $391,909.00
SophiaTX Market Capitalization Achieves $391,909.00
Philip Morris International Inc.  Expected to Post Earnings of $1.25 Per Share
Philip Morris International Inc. Expected to Post Earnings of $1.25 Per Share


© 2006-2019 Ticker Report